Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Santini, Emanuela ^a   Sgambato Faure, Veronique ^b,c   Li, Qin ^d,e   Savasta, Marc ^b   Dovero, Sandra ^d   Fisone, Gilberto ^a   Bezard, Erwan ^d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UMR 5287   (France)

^e INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPA RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN DARPP 32; PROTEIN S6; RAS PROTEIN;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DYSKINESIA; DYSTONIC DISORDER; FEMALE; GOLD STANDARD; MACACA; MOTOR DYSFUNCTION; NONHUMAN; PROTEIN PHOSPHORYLATION; REFLEX DISORDER; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; PARKINSONISM; PATHOLOGY;

PARKINSONIA; PRIMATES; RODENTIA;

ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DYSKINESIAS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; LEVODOPA; MACACA MULATTA; MAP KINASE SIGNALING SYSTEM; PARKINSONIAN DISORDERS; RAS PROTEINS;

EID: 77957870263     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012322     Document Type: Article

References (21)

1. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism- chronic treatment with L-dopa. N Engl J Med 280: 337-345.
2. Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9: 665-677.
3. Aubert I, Guigoni C, Hakansson K, Qin L, Dovero S, et al. (2005) Increased D1 dopamine receptor signalling in levodopa-induced dyskinesia. Ann Neurol 57: 17-26.
4. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, et al. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6: 501-506.
5. Pavon N, Martin AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59: 64-74.
6. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, et al. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27: 6995-7005.
7. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal Pattern of Striatal ERK1/2 Phosphorylation in a Rat Model of L-DOPA-Induced Dyskinesia and the Role of Dopamine D1 Receptors. Biol Psychiatry.
8. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22: 5042-5054.
9. Bezard E, Ferry S, Mach U, Stark H, Leriche L, et al. (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Med 9: 762-767.
10. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, et al. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J Neurosci 21: 6853-6861.
11. Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, et al. (2006) Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J Neurosci 26: 8653-8661.
12. Fernagut PO, Li Q, Dovero S, Chan P, Wu T, et al. (2010) Dopamine transporter binding is unaffected by chronic L-DOPA treatment: relevance to imaging studies. submitted.
13. Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, et al. (2010) Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2: 28ra28.
14. Berton O, Guigoni C, Li Q, Bioulac BH, Aubert I, et al. (2009) Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry 66: 554-561.
15. Snyder GL, Girault JA, Chen JY, Czernik AJ, Kebabian JW, et al. (1992) Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine. J Neurosci 12: 3071-3083.
16. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16: 1179-1188.
17. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
18. Santini E, Heiman M, Greengard P, Valjent E, Fisone G (2009) Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal 2: ra36.
19. Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, et al. (2009) L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108: 621-633.
20. Corvol JC, Muriel MP, Valjent E, Feger J, Hanoun N, et al. (2004) Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24: 7007-7014.
21. Kim DS, Palmiter RD, Cummins A, Gerfen CR (2006) Reversal of supersensitive striatal dopamine D(1) receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 137: 1381-1388.